Docket No: AM101119

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Christopher William ASTON et al.

Application No.:

10/706791

Group Art No.:

Filed:

November 12, 2003 Examiner:

For:

METHODS AND COMPOSITIONS FOR TREATING

NEUROLOGICAL DISORDERS

Confirmation No.:

Customer Number:

25291

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV100594117US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date

Carole K. Kamrad

Docket No: AM101119 Patent

2.	This Information Disclosure Statement									
	a. b.	\bowtie	is filed within three months of the filing date of the application. is filed before the mailing date of a first Office Action on the merits.							
	C.		is filed before the mailing date of a first Office Action after the filing of a							
	d.		request for continued examination under 37 CFR 1.114. is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes							
	e.		a certification under 37 CFR 1.97(e) <u>or</u> the fee set forth in 37 CFR 1.17(p). is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), <u>and</u> (ii) the fee set forth in 37 CFR 1.17(p).							
3.			fication under 37 CFR 1.97(e) and 1.704(d) undersigned attorney certifies							
	a.		that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or							
	b.		that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any							
	c.		individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement. The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.							
		A leg attac applic nation	y Cited Information ible copy of the patents, publications or other information cited on the hed form PTO 1449 is enclosed, except that no copy of a pending U.S. cation is enclosed, and if this patent application was filed or entered the nal stage after June 30, 2003, no copy of a U.S. patent or U.S. patent cation publication is enclosed.							
		No co form to the unde	ously Cited Information opy of the patents, publications or other information cited on the attached PTO-1449 is enclosed because it has been previously cited by or submitted office in a prior application which is relied upon for an earlier filing date of 35 USC 120.							
		Prior	application is Application Number , filed on of for							

Docket No: AM101119
Patent

Concise Explanation Documents cited above which are not in the English Language have been explained in the specification. a. have an abstract (or other concise explanation) in English enclosed or if b. readily available a translation into English of the document is enclosed. Form PTO-1449 is enclosed in duplicate. Fees Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00 Method of Payment of Fees: Charge Deposit Account No. 01-1425 in the amount of \$0.00 A duplicate of this statement is enclosed. Instructions as to Overpayment/Underpayment: Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.

> Bill T. Brazil Agent for Applicants Reg. No. 50,733

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (732) 274-4843

			OIPE	۸	
		2	JAN 1 3 2004 R	Co	omplete if Known
Substitute for form 1449/	10	園	44	Application Number	10/706791
INFORM	MATION DIS	CLOSURE	PADEMARK OFFE	Filing Date	November 12, 2003
STATE	MENT BY AP	PLICANT	RADEMARK	First Named Inventor	Christopher William Aston
(use as ma	ny sheets a	s necessary)		Group Art Unit	
(use us ma	,			Examiner Name	
Sheet	1	of	1	Attorney Docket Number	AM101119

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Doc	cument	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines,		
		Number (If known)	Kind Code (If Known)		Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant		
	No.	Office	Number	Kind Code (If Known)	Applicant of Cited document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т	

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т			
	1.	MAXINE A. LESNIAK et al., Receptors for Insulin-like Growth Factors I and II: Autoradiographic Localization in Rat Brain and Comparison to Receptors for Insulin, Endocrinology, 1988, 123(4):2089-2099				

		_	
Examiner	Date	•	
Signature	Con	sidered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.